GAVRETO Now approved

Introducing GAVRETO™—the only once-daily targeted RET therapy for patients with RET fusion+ metastatic NSCLC.1

NSCLC=non–small cell lung cancer; RET=rearranged during transfection.

NSCLC=non–small cell lung cancer; RET=rearranged during transfection.

NCCN

Recommended

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend pralsetinib (GAVRETO) as a preferred first-line treatment option for RET fusion-positive metastatic NSCLC (NCCN Category 2A).*2

NCCN=National Comprehensive Cancer Network®.
*See the NCCN Guidelines® for NSCLC for detailed recommendations, including other preferred options.